Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;14(11):E537-E542.
doi: 10.5489/cuaj.6722.

Controversies in the management of clinical stage 1 testis cancer

Gregory J Nason  1 , Peter Chung  2 , Padraig Warde  2 , Robert Huddart  3 , Peter Albers  4 , Christian Kollmannsberger  5 , Christopher M Booth  6 , Aaron R Hansen  7 , Philippe L Bedard  7 , Lawrence Einhorn  8 , Craig Nichols  9 , Ricardo A Rendon  10 , Lori A Wood  11 , Michael A S Jewett  1 , Robert J Hamilton  1
Affiliations

Controversies in the management of clinical stage 1 testis cancer

Gregory J Nason et al. Can Urol Assoc J. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Chung has received honoraria from Sanofi and has participated in clinical trials supported by AbbVie. Dr. Kollmannsberger has been an advisory board member for Astellas, BMS, Novartis, Pfizer, and Sanofi; has received honoraria from BMS, Novartis, and Pfizer; and has participated in clinical trials supported by Astellas, AstraZeneca, BMS, Janssen, Merck, Novartis, Pfizer, and Sanofi. Dr. Rendon has been an advisory board and speakers’ bureau member for, and has received honoraria from AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Jansen, and Sanofi. Dr. Wood has been an advisory board member (with no compensation) for Astellas, Pfizer, and Novartis; and has participated in clinical trials supported by Aragon, AstraZeneca, BMS, Exelixis, Merck, Pfizer, and Roche. Dr. Jewett has been an advisory board member for Pfizer and Theralase Tech; has received honoraria from Olympus, Pfizer, and Theralase Tech; and holds investments in Theralase Tech. The remaining authors report no competing personal or financial interests related to this work. The remaining authors report no competing personal or financial interests related to this work.

References

    1. Canadian Cancer Statistics. A 2018 special report on cancer incidence by stage. [Accessed May 18, 2020]. Available at: www.cancer.ca.
    1. Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68:1054–68. doi: 10.1016/j.eururo.2015.07.044. - DOI - PubMed
    1. Kollmannsberger C, Tandstad T, Bedard PL, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol. 2015;33:51–7. doi: 10.1200/JCO.2014.56.2116. - DOI - PubMed
    1. de Wit R, Bosl GJ. Optimal management of clinical stage I testis cancer: One size does not fit all. J Clin Oncol. 2013;31:3477–9. doi: 10.1200/JCO.2013.51.0479. - DOI - PubMed
    1. Tandstad T, Cohn-Cedermark G. Primum non nocere: What hurts in clinical stage I testicular cancer? J Clin Oncol. 2015;33:2318–9. doi: 10.1200/JCO.2015.61.1152. - DOI - PubMed

LinkOut - more resources